MC-5A for Chemotherapy Induced Peripheral Neuropathy

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Painful chemotherapy induced peripheral neuropathy (CIPN) is a common complication of cancer therapy with few treatment options. CIPN is a complex side effect that varies between individuals and can be difficult to describe, difficult to treat and can significantly effect quality of life for patients.

The purpose of this study is to determine if patients with painful CIPN will have a decrease in pain scores after treatment with the MC-5A device.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison

Criteria

Inclusion Criteria:

• painful peripheral neuropathy resulting from chemotherapy

• pain must be present for minimum of 6 months

• must be able to read/understand English

• stable analgesics regimens allowed (no change for past 7 days)

Exclusion Criteria:

• painful peripheral neuropathy that is not the result of chemotherapy

• pregnant women

• patients unable to wean off anti-epileptics

• patients currently receiving chemotherapy known to cause peripheral neuropathy

• patients with pacemakers or implanted defibrillators

• patients with vena cava or aneurysm clips

• patients with a history of epilepsy